New study shows TLX250-Px PET/CT can detect various kidney cancer types, not just clear cell RCC.

Telix Pharmaceuticals announced a new independent analysis of its Phase 3 ZIRCON trial data, published in European Urology, demonstrating that TLX250-Px (Zircaix®) PET/CT imaging is highly predictive of renal malignancies across all subtypes, including non-clear cell renal cell carcinoma (nccRCC). The study showed a 98% positive predictive value, 82% sensitivity, and 87% specificity, suggesting TLX250-Px could improve diagnosis and management of kidney cancers beyond just clear cell RCC. This expands the potential clinical use of TLX250-Px, which was originally developed for clear cell RCC detection. Further evaluation is anticipated to confirm its broader application in renal cancer care.